
PERSONAL DETAILS

NAME: Michael A O'Rorke

WORK ADDRESS: Room S451, College of Public Health, 145 N. Riverside Drive, Iowa City, IA 52242

Tel: +1 319-384-1560 | **E-mail:** michael-ororke@uiowa.edu | **Twitter:** @michael_ororke

EDUCATION

2003-2007 - BSc (Hons) Physiotherapy

Faculty of Life & Health Sciences, University of Ulster, Northern Ireland

2007-2011 – Doctor of Philosophy (PhD) – Cancer Epidemiology

School of Medicine, Dentistry & Biomedical Sciences, Queens University, Belfast, Northern Ireland.

Thesis title: Physical activity, nutrition and the aetiology of upper gastrointestinal tract cancers

Supervisors: Professor Liam Murray and Dr Marie Cantwell

Funding: Awarded by the Department for Employment and Learning (DEL).

2012 – Post Graduate Certificate in Higher Education Teaching (PGCHET)

School of Education, Queens University, Belfast, Northern Ireland

RESEARCH POSITIONS

Nov 2011 – Feb 2014 Postdoctoral Research Fellow (pharmacoepidemiology)

School of Pharmacy/Centre for Public Health, Queen's University Belfast

Principal Investigator(s): Prof Liam Murray, Prof Carmel Hughes & Dr Chris Cardwell

Summary: I created a clinical pathological dataset in the Northern Ireland cancer registry with onward electronic linkage to the Northern Ireland primary care dispensing database for the investigation of unintended chemo-preventative effects of commonly prescribed medications including anti-hypertensives, statins and aspirin use.

COMPETITIVELY AWARDED FELLOWSHIP

Feb 2014 – Aug 2017 Cancer Research UK Population Research Committee Postdoctoral Fellowship

Host Institution: *Centre for Public Health, Queen's University Belfast*

Project: Beta-adrenergic receptor expression and beta-blocker drug use: association with breast cancer survival and prognosis

Funding: £151,216, including salary for the fellow over 3 years

Summary: This is a novel molecular pharmacoepidemiological study involving linkages to province-wide cancer records, primary care dispensed medication data and archived tumour tissue of 1,266 stage I-IV breast cancer patients diagnosed in Northern Ireland from 2009 to 2014. The study aims to determine whether the level of beta-adrenergic receptor expression, in combination with incidental beta-blocker drug use enhances breast cancer survival and prognosis. Ultimately, this study may determine whether such drugs would be useful additions to the standard treatment of breast cancer, in particular patient subgroups, providing the rationale for a clinical trial.

<http://www.cancerresearchuk.org/funding-for-researchers/applying-for-funding/how-to-make-a-successful-application/successful-applicant-case-studies/post-doc-in-epidemiology-michael-o%E2%80%99rorke>

Oct 2016 to Aug 2018 UKCRC Centre of Excellence for Public Health Northern Ireland

Role: Knowledge, Transfer and Exchange (KTE) Officer

Summary:

Whilst finishing my CRUK fellowship, I am now the Knowledge Exchange Officer for the Centre of Excellence for Public Health in Northern Ireland, one of five UK CRC centres of excellence in the UK

<http://www.ukcrc.org/research-coordination/joint-funding-initiatives/public-health-research/>. This role also involves coordination of the Northern Ireland Public Health Research Network <http://www.thehealthwell.info/niphnrn/about-niphnrn>, which facilitates multi-sectoral collaboration between academics and the third and statutory sectors for the development of high quality research proposals for public health interventions. My role is to help foster and build relationships and networks with, among and between researchers and potential users of this information (practitioners/policy makers/patients and the general public). To facilitate this role I have applied to the Royal Society Pairing Scheme <https://royalsociety.org/grants-schemes-awards/pairing-scheme/> to gain an insight into the world of UK parliamentarians and civil servants.

Aug 2018 to Present University of Iowa, College of Public Health, Dept. Epidemiology
Role: Assistant Professor, molecular epidemiology of Cancer

TEACHING EXPERIENCE

I have lectured recurrently on a variety of modules in the past 7 years. I currently engage in approximately 20 hours of voluntary teaching every year; summarised in the table below:

Dates	Module/Course	Type	Topic	Duration (hrs/yr)
2011-2018	MED2015 Bachelor of medicine	Tutorial	Year 2 - Epidemiology	12
2015-2018	MB, BCh, BAO: Bachelor of medicine	Tutorial	Year 1 - Diagnostic studies	4
2013-2018	MSc Public Health	Lecture	Sun exposure and/or obesity	1
2013-2018	Student Select Component MB, BCh, BAO: Bachelor of medicine	Lecture	Cancer screening in high risk populations	1
2012-2018	SCM3001 BSc Hons Human Biology & BSc Hons Food Quality, Safety & Nutrition	Lecture	Hypertension	1
2014-2016	MSc Bioinformatics and Computational Genomics	Lecture	Introduction to epidemiology	2

PhD, MSc and undergraduate student supervision:

2013	Informal supervisory support for MSc Public Health Student
2014	Supervisor for summer studentships (supervised two medical students for 2 months)
2014	Informal supervisory support for final year PhD student (academic maternity cover)
2015-2016	School of Medicine & Dentistry 'buddy' scheme mentor to 2 PhD students

PEER-REVIEWED PUBLICATIONS

Published (20, 8 first author)

Gómez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Márquez M, Rava M, Michalski CW, Farré A, Molero X, Löhr M, Perera J, Greenhalf B, **O'Rorke M**, Tardon A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellví L, Domínguez-Muñoz E, Balsells J, Costello E, Yu J, Iglesias M, Ilzarbe L, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Lawlor RT, Ye W, Hidalgo M, Scarpa A, Sharp L, Carrato A, Real FX, Furlong L, Malats N. on behalf of the PanGenEU Study Investigators. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. *International J Epidemiology* 2018 (Accepted ahead of publication).

Van der Graaf P, Francis O, Doe E, Barrett E, **O'Rorke M**, Docherty G. Structural approaches to knowledge exchange: comparing practices across five centres of excellence in public health. *J Public Health*. 2018; 1;40 (suppl_1):i31-i38. PMID:29538725.

Spence AD, Busby J, Murchie P, Kunzmann AT, McMenamin ÚC, Coleman HG, Johnston BT, **O'Rorke MA**, Murray LJ, Iversen L, Lee AJ, Cardwell CR. Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer: An analysis of two independent population-based databases. *Int J Cancer*. 2018. doi: 10.1002/ijc.31293. [Epub ahead of print]

Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, Ilzarbe L, **O'Rorke M**, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, Malats N; PanGenEU Study Investigators. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. *Int J Epidemiol*. 2018. doi: 10.1093/ije/dyx269 [Epub ahead of print]

Gomez-Rubio P, Rosato V, Márquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W, **O'Rorke M**, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong L, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. *Ann Oncol*. 2017; 28(7):1618-1624.

Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, **O'Rorke M**, Visvanathan K, Cronin-Fenton D, De Schutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. *Breast Cancer Res*. 2016. 1;18(1):119.

O'Rorke MA, Murray LJ, Brand JS, Bhoo-Pathy N. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. *Cancer Treat Rev*. 2016; 47:12-2.

Anderson LA, **O'Rorke MA**, Wilson R, Jamison J, Gavin AT; Northern Ireland HPV Working Group. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland. *J Med Virol*. 2016; 88(7):1262-70.

Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, **O'Rorke M**, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. *Gut*. 2015 [Epub ahead of print] doi: 10.1136/gutjnl-2015-310442.

O'Rorke MA, Murray LJ, Hughes CM, Cantwell MM, Cardwell CR. The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink. *Cancer Causes Control*. 2015; 26 (3):355-66.

Titmarsh GJ, Duncombe AS, McMullin MF, **O'Rorke MA**, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *Am J Hematol*. 2014; 89(6):581-7.

McShane CM, Murray LJ, Landgren O, **O'Rorke MA**, Korde N, Kunzmann AT, Ismail MR, Anderson LA. Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. *Cancer Epidemiol Biomarkers Prev.* 2014; 23(2):332-42.

Abdullah F, **O'Rorke M**, Murray L, Su TT. Evaluation of a worksite cervical screening initiative to increase Pap smear uptake in Malaysia: a cluster randomized controlled trial. *Biomed Res Int.* 2013; 2013:572126.

Wilson JC, **O'Rorke MA***, Cooper JA, Murray LJ, Hughes CM, Gormley GJ, Anderson LA. Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink. *Cancer Epidemiol.* 2013 Dec;37(6):897-904.

*Joint first authorship

Bannon FJ, **O'Rorke MA***, Murray LJ, Hughes CM, Gavin AT, Fleming SJ, Cardwell CR. Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the Clinical Practice Research Datalink. *Cancer Causes Control.* 2013 Nov; 24(11):2027-34.

*Joint first authorship

Anderson L, **O'Rorke M**, Jamison J, Wilson R, Gavin A; HPV Working Group members. Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from Northern Ireland and a systematic review and meta-analysis. *J Med Virol.* 2013 Feb; 85(2):295-308.

O'Rorke MA, Black C, Murray LJ, Cardwell CR, Gavin AT, Cantwell MM. Do perinatal and early life exposures influence the risk of malignant melanoma? A Northern Ireland birth cohort analysis. *Eur J Cancer.* 2013 Mar; 49(5):1109-16

O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA.

Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. *Oral Oncol.* 2012; 48(12):1191-201.

O'Rorke MA, Cantwell MM, Abnet CC, Brockman AJ, Murray LJ; FINBAR Study Group. Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. *Int J Cancer.* 2012; 131(8):1882-91.

O'Rorke MA, Cantwell MM, Cardwell CR, Mulholland HG, Murray LJ. Can physical activity modulate pancreatic cancer risk? a systematic review and meta-analysis. *Int J Cancer.* 2010; 126(12):2957-68.

Submitted (3, 1 first author)

Humphries MP, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, Parkes EE, **O'Rorke MA**, Irwin GW, McArt DG, Kennedy RD, Mullan PB, McQuaid S, Salto-Tellez M and Buckley NM. Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer. *J Oncol* (Special issue 'Strategies to Improve Cancer Immunotherapy').

Kong YC, Bhoo-Pathy N, **O'Rorke MA**, Subramaniam S, See MH, Jamaris S, Teoh KH, Bustam AZ, Looi LM, Taib NA, Yip CH (2018). Association between method of biopsy and survival following breast cancer. *Journal of Surgery* (Submitted)

O'Rorke MA, De Schutter H, Vaes E, Margenthaler J, Gao F, Caan B, Weltzien E, Hanna GG, Dent R, Wong FY, Tan B, Rapiti E, Taib NA, Yip CH, Tan EY, Hartman M, Verkooijen HM, Kwong A, Toi M, Takada M, Murray LJ and Bhoo-Pathy N. The prognostic value of adjuvant radiotherapy in triple negative breast cancer: a pooled analysis of eleven cohorts from three continents. *Eur J Cancer* (Submitted)

In progress (3, 2 first author)

Molina-Montes E, van Hoogstraten L, Gómez-Rubio P, Márquez M, Löhr M, Sharp L, Molero X, Michalski CW, Farré A, Perea J, **O'Rorke M**, Greenhalf W, Ilzarbe L, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvis L, Domínguez-Muñoz E, Balsells J, Costello E, Iglesias M, Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Ye W, Hidalgo M, Carrato A, Lawlor R, Real FX, Malats N on behalf of the PanGenEU Study Investigators. Pancreatic cancer risk in relation to lifetime smoking patterns, tobacco type and dose-response relationships.

O'Rorke MA, McQuaid S, Cardwell CR, Lioe T, Boyd C, Ervine A, Cameron I, Hughes C, Cantwell MM, Powe DG, Murray LJ. Beta-blocker drug use, Beta-adrenergic receptor expression and breast cancer-specific survival.

O'Rorke MA, Dent R, Wong FY, Tan B, Rapiti E, Taib NA, Yip CH, Tan EY, Hartman M, Verkooijen HM, Kwong A, Toi M, Takada M, Murray LJ and Bhoo-Pathy N. The prognostic value of adjuvant chemotherapy in T1N0M0 triple negative breast cancer.

CONTRIBUTION TO BOOK CHAPTER

(1, 0 first author)

Authors: Marie C Bradley, **Michael A O'Rorke**, Janine A Cooper, Søren Friis, Laurel A Habel.

Chapter 23: 'Pharmaceuticals other than hormones'

Book: Cancer Epidemiology and Prevention, 4th Edition (Oxford University Press)

Editors: Michael Thun, James Cerhan, Christopher Haiman, Martha Linet and David Schottenfeld.

2015-2017 PUBLISHED ABSTRACTS

Published (9, 3 first author)

Molina-Montes E et al. on behalf of the PanGenEU study Investigators. Association between gallbladder disease and pancreatic cancer risk according to tumour characteristics. *Pancreatology*. 2017. 17 (3) Suppl, pp S96–S97 Abstract ID: 2022

Santibañez M, Murray LJ, Anderson L, Alguacil J, Uuksulainen S, **O'Rorke M**, Sharp L, Kauppinen T, on behalf of the FINBAR study group. Occupational exposures and reflux esophagitis, barrett's oesophagus, and esophageal adenocarcinoma *OEM* 2016;73 (Suppl 1):A1–A250 Abstract ID: P047

O'Rorke MA, Murray LJ and Bhoo-Pathy N. Overall survival in triple-negative breast cancers - Prognostic influence of type of surgery and adjuvant radiotherapy: A systematic review and meta-analysis. *San Antonio Breast Cancer Symposium* 2015. P3-12-10

O'Rorke M, Anderson L, Wilson R, Jamison J, Gavin A. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: a population-based study from Northern Ireland. *European Journal of Cancer Care*. 2015; 24 (S1): p-82

O'Rorke M, Murray L, Hughes C, Cantwell M, Cardwell C. The effect of warfarin therapy on breast, colorectal, lung and prostate cancer survival: a population based cohort study using the Clinical Practice Research Datalink. *European Journal of Cancer Care*. 2015; 24 (S1): p-154

Gomez-Rubio P, et al. Asthma and nasal allergies associate with reduced pancreatic cancer risk. *Pancreatology* 06/2015; 15(3):S124-S125

Gomez-Rubio P, et al. Patterns of comorbidity and multimorbidity in pancreatic cancer patients. *Pancreatology* 06/2015; 15(3):S125.

Santibañez M, **O'Rorke M**, O'Leary E, De Camargo Cancela M, Murray L, Sharp L. Allergies, asthma and the risk of pancreatic cancer: A population-based case-control study in Ireland. *European Respiratory Journal* 2015 46(suppl 59):PA3389

Santibáñez M, O'Rorke M, O'Leary E, De Camargo Cancela M, Murray L, Sharp L. Diabetes, pancreatitis and smoking and pancreatic cancer risk: results from a population-based case-control study in Ireland. Irish Journal of Medical Science 2015 184:S229-S229

2012-2017 CONFERENCE PRESENTATIONS (highlights)

Invited talks:

Title: 'NSAIDs and brain tumour risk: a nested case control study using data from the CPRD.'

Presented at: 28th International Conference on Pharmacoepidemiology (ISPE), Barcelona **(Oral)** - 25/08/2012

Title: 'Increasing incidence of HPV-related head and neck cancers and association with survival'

Presented at: Head and neck cancer symposium – National University of Ireland, Galway **(Oral)** – 17/05/2013

Title: 'Early-life and perinatal factors and risk of malignant melanoma'

Presented at: Melanoma focus, Bristol **(Oral)** – 26/04/2013

Media: http://www.ejcancer.com/pb/assets/raw/Health%20Advance/journals/ejc/EJCNews_March2013.pdf

Title: 'Warfarin therapy and breast, colorectal, lung and prostate cancer survival'

Presented at: Vanderbilt University Cancer Symposium – Nashville, TN **(Oral)** – 13/10/2015

Kaiser Permanente Research Division – San Francisco, CA **(Oral)** – 15/10/2015

Title: 'The Pancreatic Cancer Aetiology and Management study (PanCAM study)'

Presented at: Pancreatic Cancer Research Day – CCRCB QUB, Belfast **(Oral)** – 07/03/2016

Title: 'The Centre of Excellence on tour'

Presented at: UKCRC Progress and Pathways – Royal College of Physicians, London **(Oral)** – 29/06/2017

Title: 'The Molecular Epidemiology of Cancer: Past Endeavors, Current Studies, and Future Directions'

Presented at: College of Public Health, Department of Epidemiology, University of Iowa **(Oral)** – 08/02/2018

<https://biology.uiowa.edu/about/seminars/molecular-epidemiology-cancer-past-endeavors-current-studies-and-future-directions>

Other:

Title: 'Beta-adrenergic receptor expression, beta-blocker drug use and breast cancer survival'

Presented at: Joint QUB, Vanderbilt cancer symposium, Belfast **(Oral)** – 01/10/2014

Title: "Warfarin therapy and breast, colorectal, lung and prostate cancer survival"

Presented at: 5th UKCRC Public Health Centres of Excellence conference **(Oral)** – Leeds, 18-20th June 2014

Title: 'Impact of adjuvant radiotherapy on survival in triple-negative breast cancers'

Presented at: San Antonio breast cancer symposium – San Antonio, TX, USA **(Poster)** – 11/12/2015

SMDBS annual Postdoc Soc symposium - QUB, Belfast **(Oral)** – 11/03/2016

Queen's Postdoctoral Showcase Event - QUB, Belfast **(Poster)** – 12/09/2017

Title: 'Impact of adjuvant radiotherapy on survival in triple-negative breast cancers'

Presented at: 6th UKCRC Public Health Centres of Excellence National conference **(Poster)** – Edinburgh 18-20th November 2015

Title: 'HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix' and 'Warfarin therapy and breast, colorectal, lung and prostate cancer survival'

Presented at: National Cancer Intelligence Network (NCIN), Belfast **(2 x Posters)** - 10/06/2015

Title: 'HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix'

Presented at: All-Ireland Cancer Conference (AICC), Belfast **(Poster)** - 11/05/2015

2013-2017 PEER REVIEW ACTIVITY

2014-2017 Editorial board member - the World Journal of Meta-Analysis (WJMA)

Over this period I have also reviewed papers for JAMA, Int J Cancer, Br J Cancer, BMC Cancer, Am J Clin Nut, Clin Microbiol Infec, World J Gastroenterol, Sci Total Environ, Cancers and Biosci Rep.

ACHIEVEMENTS

2009 I obtained a scholarship through the Ireland-Northern Ireland National Cancer Institute Consortium, to attend a one month course on the 'principles and practice of cancer prevention and control', in Washington DC.

2009 1st Prize School of Medicine, QUB PhD Showcase Event (won a Dell laptop)

2012 Most cited research paper in Oral Oncology since 2012 - <http://www.journals.elsevier.com/oral-oncology/most-cited-articles>

2014 QUB, SMDBS Annual Celebration of Excellence – Best Post-Doctoral Research Fellow (nominee)

2015 Facilitator at national CRUK sandpit event 'Risk perception and cancer prevention' -

<http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/population-research-innovation-workshops>

2015 Travel award (Northern Ireland Cancer Translational Research Group (CTRG))

ADMINISTRATIVE EXPERIENCE & PUBLIC ENGAGEMENT

2007-2017 Member of Cancer Epidemiology & Health Services Research Group Journal club

2011-2012 Student representative for the PGCHET Staff Student Consultative Committee

2011-2016 Member of Primary Care Research Group journal club (School of Pharmacy)

2012 Nutrition Society Conference (managed the audio-visual setup for 3 days for >400 international delegates)

2012-2014 Elected chair of the School of Medicine, Dentistry and Biomedical Sciences Postdoctoral Society

2014-2018 STEMNET Ambassador <http://www.stemnet.org.uk/ambassadors/> (public engagement/outreach)

2015-2016 Centre for Cancer Research & Cell Biology open day (public engagement)

2014 'Cancer research advancing patient care' (public engagement activity)

2014 'CRUK all-party working group – early diagnosis of cancer', Stormont Executive (policy engagement)

2014-2016 Queen's University Human Tissue Act (HTA) audits (PanCAM study and CRUK fellowship study)

2014-2017 Northern Ireland Science Festival (organisation of Public Engagement Activity)

2014-2017 Culture Night Belfast (organisation of Public Engagement Activity)

2017 QUB research showcase event (organisation of Public Engagement Activity)

2017 Science Uncovered (organisation of Public Engagement Activity)

PROFESSIONAL MEMBERSHIPS

2012- Present Fellow of the Higher Education Academy (FHEA)